Global Chinese Hamster Ovary (CHO) Cells Market, By Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System and Others), Application (Biologics and Medical Research), End User (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, Others), Distribution Channel (Direct Tenders, Retail Sales and Others) - Industry Trends and Forecast to 2030.
Chinese Hamster Ovary (CHO) Cells Market Analysis and Insights
One significant driver of the CHO cell market is the continued growth of monoclonal antibodies (mAbs) in the pharmaceutical industry. CHO cells are integral to the production of mAbs, which are used in the treatment of various diseases, including cancer and autoimmune disorders. The expansion of mAb-based therapies, coupled with ongoing research and development in this field, has fueled the demand for CHO cells. The market also benefits from increased research and development efforts aimed at improving cell line development and bioprocess optimization. These advancements help enhance the efficiency and productivity of CHO cell-based biomanufacturing, reducing production costs and timelines.
However, the market faces challenges such as the high cost of maintaining Chinese Hamster Ovary Cells (CHO) cultures, lack of skilled personnel, and complex regulatory requirements.
The global Chinese Hamster Ovary (CHO) cells market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.5% in the forecast period of 2023 to 2030 and is expected to reach USD 659,479.05 thousand by 2030 from USD 354,047.75 thousand in 2022.
Global Chinese Hamster Ovary (CHO) cells market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, ASP in USD, and Volume in Thousand
|
|
Segments Covered
|
Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System and Others), Application (Biologics and Medical Research), End User (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, Others), Distribution Channel (Direct Tenders, Retail Sales and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East And Africa
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Promega Corporation, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, GTP Bioways and Curia Global, Inc. and among others
|
Market Definition
Chinese Hamster Ovary (CHO) cells are a type of mammalian cell line commonly used in biotechnology and biomedical research, particularly in the field of cell culture and bioprocessing. These cells have become essential tools in biotechnology and biomedical research. CHO cells are known for their adherence to culture surfaces, robust growth characteristics, and ability to express recombinant proteins. Their popularity stems from their similarity to human cells, making them suitable for studying biological processes and producing biopharmaceuticals.
Global Chinese Hamster Ovary (CHO) Cells Market Dynamics
Drivers
- Rising use of CHO Cells in the Genetic Study
Chinese Hamster Ovary (CHO) cells are an epithelial cell line derived from the Chinese hamster ovary that is commonly used in biological and medical research and commercially for the production of therapeutic recombinant DNA proteins. They have found widespread use in genetics, toxicity screening, nutrition and gene expression studies, especially recombinant protein expression. CHO cells are the most commonly used mammalian host for the industrial production of recombinant protein drugs.
The increasing use of Chinese Hamster Ovary (CHO) cells in genetic studies reflects their unique advantages in the field of genetic research.
CHO cells are renowned for their genetic stability. This means that their genetic makeup remains relatively constant across multiple cell generations, making them an excellent choice for genetic studies. Researchers can confidently manipulate and study specific genes or genetic modifications without the concern of unexpected genetic changes interfering with their experiments. This stability is particularly crucial when conducting precise gene editing, knockout studies, or investigating the long-term effects of genetic modifications.
- Growing Demand for Biopharmaceuticals
One significant driver of the demand for biopharmaceuticals is their effectiveness. These drugs have demonstrated remarkable therapeutic outcomes in areas such as oncology, autoimmune diseases, and rare genetic disorders. For instance, monoclonal antibodies, a common type of biopharmaceutical, have transformed cancer treatment by targeting cancer cells directly while sparing healthy ones. Biopharmaceuticals also offer promising approaches to managing previously untreatable conditions and rare diseases, which were often neglected by traditional drug development due to their limited patient populations.
Opportunity
-
Continuous Development of Cell Culture Technologies
The continuous development of cell culture technologies is a critical aspect of biopharmaceutical manufacturing and biotechnology research. These advancements play a pivotal role in improving the production of biologic drugs, vaccines, and other biotechnological products.
Restraint / Challenge
-
High Cost of CHO Cell-Based Production
The high cost of Chinese Hamster Ovary (CHO) cell-based production is a significant restraint within the biopharmaceutical manufacturing industry. There are several factors that contribute to the elevated costs.
Firstly, the upstream process in CHO cell-based production is complex. It involves the cultivation of mammalian cells in bioreactors, which necessitates strict control over various parameters such as temperature, pH, oxygen levels, and nutrient supply. Maintaining these optimal conditions for cell growth and protein expression requires specialized equipment and skilled personnel, adding to the overall cost.
- Time-consuming and inconsistency in cho cell line development process
The development of Chinese Hamster Ovary (CHO) cell lines for biopharmaceutical production is a complex and time-consuming process that is often marked by variability and challenges. This process begins with the introduction of specific genes or genetic modifications into CHO cells, which will enable them to express and produce the desired biological drug or protein. However, this initial step can be inefficient, as not all cells will successfully incorporate the genetic material, leading to variability in protein expression levels.
Recent Developments
- In July 2023, Merck KGaA announced that it is expanding its facility in Lenexa, Kansas, USA, adding 9,100 square meters of laboratory space and production capacity for the production of cell culture media. The investment in the region reflects the company's strategy to expand and diversify its supply chain to meet current and future demand for cell culture platforms.
- In February 2022, Sartorius AG acquired the business from Novasep, and added a complementary offering to its chromatography portfolio. The acquired portfolio includes chromatography systems primarily suited for small biomolecules such as oligonucleotides, peptides, and insulin, and innovative systems for the continuous production of biopharmaceuticals.
Global Chinese Hamster Ovary (CHO) Cells Market Scope
Global Chinese Hamster Ovary (CHO) cells market is categorized into five notable segments based on type, system, application, end user, and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Services
- Product
On the basis of type, the market is segmented into services and product.
System
- Metabolic Selection System
- Antibiotic Selection System
- Others
On the basis of systems, the market is segmented into metabolic selection system, antibiotic selection system and others.
Application
- Biologics
- Medical Research
On the basis of application, the market is segmented into biologics and medical research.
End User
- Biopharmaceutical Companies
- Biotechnology Companies
- Clinical Development and Manufacturing Organizations
- Clinical Research Organizations
- Academic Institutes and Research Organizations
- Others
On the basis of end user, the market is segmented into biopharmaceutical companies, biotechnology companies, clinical development and manufacturing organizations, clinical research organizations, academic institutes and research organizations and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tenders, retail sales, and others.
Global Chinese Hamster Ovary (CHO) Cells Market Regional Analysis/Insights
The market is categorized into five notable segments such as type, system, application, end user, and distribution channel.
The countries covered in this market report are U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East And Africa.
U.S. is expected to dominate North America due to the presence of key market players in the largest consumer market with high GDP. The Germany dominates Europe region due to strong presence of key players. China dominates Asia-Pacific region due to the mass production of Chinese hamster ovary (CHO) cells based products and increasing demand from emerging markets and expansion.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Chinese Hamster Ovary (CHO) Cells Market Share Analysis
Global chinese hamster ovary (CHO) cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the Global Chinese Hamster Ovary (CHO) cells market.
Some of the major players operating in the Global Chinese Hamster Ovary (CHO) cells market are Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Promega Corporation, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, GTP Bioways and Curia Global, Inc. and among others.
SKU-